Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3500
+0.0004 (+0.11%)
Official Closing Price
Updated: 8:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
May 29, 2024
Via
Investor Brand Network
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
May 29, 2024
From
Cybin Inc.
Via
Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase
May 14, 2024
Via
Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
May 14, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones
May 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
May 06, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference
April 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin to Participate at the 27th Annual Milken Institute Global Conference
April 25, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”
April 18, 2024
Via
Investor Brand Network
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
April 18, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program
April 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
April 16, 2024
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference
April 10, 2024
Via
Investor Brand Network
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day
March 18, 2024
Via
Investor Brand Network
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
March 18, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder
March 15, 2024
Via
Investor Brand Network
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
March 15, 2024
From
Cybin Inc.
Via
Business Wire
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO
March 15, 2024
Via
AB Newswire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
March 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
March 14, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast
March 13, 2024
Via
Investor Brand Network
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
March 13, 2024
From
Cybin Inc.
Via
Business Wire
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
March 12, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference
February 27, 2024
Via
Investor Brand Network
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Q3 Results, Recent Business Highlights
February 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures Two New JP Patents, Further Broadening IP Portfolio in Key Markets
February 07, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
February 07, 2024
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.